Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness
NCT ID: NCT06997952
Last Updated: 2025-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2024-05-24
2024-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
NCT02866214
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
NCT01599507
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
NCT03976115
Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis
NCT03289520
Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome
NCT07116239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
Received febuxostat daily for 12 weeks in addition to their standard treatment. The prescribed dosage was 40 mg taken once daily, self-administered by the patients.
Febuxostat 40 mg
Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.
Control
continued with their standard treatment alone
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Febuxostat 40 mg
Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CKD stages III to IV
* Asymptomatic hyper uricemia
* Stable dose of all medications including ACEIs or ARBs for blood pressure control at least three months before enrolling
Exclusion Criteria
* Acute kidney injury.
* Active and advanced malignancy.
* History of hypersensitivity to febuxostat.
* Women who are taking oral contraceptives, pregnant or lactating
* Patients with established cardiovascular disease.
* Patients with liver disease.
* Patients receiving mercaptopurine, theophylline and azathioprine.
* Patients on steroids or other immunosuppressive treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, Egypt, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS268/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.